A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Drug: LHRH AgonistDrug: Optional Endocrine Therapy of Investigator's Choice
- Registration Number
- NCT05296798
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 922
- Histologically or cytologically confirmed and documented human epidermal growth factor receptor 2 (HER2)-positive/estrogen receptor (ER)-positive adenocarcinoma of the breast with metastatic or locally-advanced disease not amenable to curative resection
- At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of ≥6 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Left ventricular ejection fraction (LVEF) of at least (≥)50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
- Adequate hematologic and end-organ function
- For women of childbearing potential: Participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 7 months after the final dose of Phesgo
- For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo
Maintenance Phase Inclusion Criteria
- Complete a minimum of four cycles to a maximum of eight cycles of induction therapy; the minimum cycles are defined as either: Phesgo injections + 4 docetaxel infusions, or Phesgo injections + 12 paclitaxel infusions
- Achieve a minimum of stable disease (SD) (or Non-complete response [CR]/Non-progressive disease [PD] for participants with non-measurable disease) (i.e., did not experience PD) according to RECIST v1.1 at the last tumor assessment during the induction therapy phase
- LVEF of ≥50% at the last assessment during the induction therapy phase
- Previous systemic non-hormonal anti-cancer therapy in the metastatic breast cancer (MBC) or advanced breast cancer (ABC) setting. Note: Up to one line of single-agent endocrine therapy given in the metastatic or locally advanced setting will be allowed.
- Prior treatment with a selective estrogen receptor degrader (SERD)
- Previous treatment with approved or investigative anti-HER2 agents in any breast cancer treatment setting, except Phesgo (or trastuzumab SC with pertuzumab IV, or pertuzumab and trastuzumab IV), single-agent trastuzumab IV or SC, ado-trastuzumab emtansine, lapatinib, and neratinib in the neoadjuvant or adjuvant setting
- Disease progression within 6 months of receiving adjuvant anti-HER2 therapy (such as trastuzumab, with or without pertuzumab [IV, SC, or fixed-dose combination], or ado-trastuzumab emtansine, or neratinib)
- Non-resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0) Grade 1 or better
- History of persistent Grade ≥2 (NCI-CTC, Version 5.0) hematological toxicity resulting from previous adjuvant or neo-adjuvant therapy
- History of exposure to the following cumulative doses of anthracyclines; Doxorubicin >360 mg/m2; Liposomal doxorubicin >500 mg/m2; Epirubucin >720 mg/m2; Mitoxantrone >120 mg/m2; Idarubicin >90 mg/m2.
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease
- Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 7 months after the final dose of Phesgo (Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of induction therapy).
- Treated with investigational therapy within 28 days prior to initiation of induction therapy
- Treated with localized palliative radiotherapy within 14 days prior to initiation of induction therapy
- Concurrent participation in any other therapeutic clinical trial
- Known hypersensitivity to any of the study medications or to excipients of recombinant human or humanized antibodies
- Current chronic daily treatment (continuous for >3 months) with corticosteroids (dose of 10 mg/day methylprednisolone or equivalent)
- Poorly controlled hypertension
- Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, active liver disease including active viral or other hepatitis virus, autoimmune hepatic disorders, or sclerosing cholangitis, current alcohol abuse, or cirrhosis
- Active cardiac disease or history of cardiac dysfunction
- Major surgical procedure or significant traumatic injury within 14 days prior to enrollment or anticipation of need for major surgery during induction therapy
- Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery
- Concurrent, serious, uncontrolled infections, or known infection with HIV with the following exception: Individuals who are HIV positive are eligible provided they are stable on anti-retroviral therapy for ≥4 weeks, have a CD4 count ≥350 cells/uL, and have an undetectable viral load and no history of AIDS-defining opportunistic infections within 12 months prior to enrollment.
- Serious COVID-19 infection within 14 days prior to enrollment; however, no screening testing for SARS-CoV-2 is required
- Serious infection requiring oral or IV antibiotics within 7 days prior to screening
- Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in the study
- History of malignancy within 5 years prior to screening with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death
- For pre- and perimenopausal women, and men: Known hypersensitivity to luteinizing hormone-releasing hormone agonist (LHRHa); Not willing to undergo and maintain treatment with approved LHRHa therapy for the duration of endocrine therapy that requires gonadal function suppression
- Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of giredestrant treatment in Arm B
- A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism, including deep vein thrombosis, unless the condition is adequately treated and under control
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Induction Therapy: Phesgo plus Taxane-Based Chemotherapy Phesgo - Induction Therapy: Phesgo plus Taxane-Based Chemotherapy Docetaxel - Induction Therapy: Phesgo plus Taxane-Based Chemotherapy Paclitaxel - Arm A, Maintenance Therapy: Phesgo LHRH Agonist - Arm A, Maintenance Therapy: Phesgo Phesgo - Arm A, Maintenance Therapy: Phesgo Optional Endocrine Therapy of Investigator's Choice - Arm B, Maintenance Therapy: Giredestrant plus Phesgo Phesgo - Arm B, Maintenance Therapy: Giredestrant plus Phesgo Giredestrant - Arm B, Maintenance Therapy: Giredestrant plus Phesgo LHRH Agonist -
- Primary Outcome Measures
Name Time Method Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1 From randomization for maintenance therapy to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 53 months)
- Secondary Outcome Measures
Name Time Method Overall Survival From randomization for maintenance therapy to death from any cause (up to 98 months) Objective Response Rate, as Determined by the Investigator According to RECIST v1.1 From randomization for maintenance therapy to disease progression or death (up to 53 months) The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart.
Duration of Response, as Determined by the Investigator According to RECIST v1.1 From first occurrence of documented objective response after randomization for maintenance therapy to disease progression or death from any cause, whichever occurs first (up to 53 months) Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1 From randomization for maintenance therapy to disease progression or death (up to 53 months) The clinical benefit rate is defined as the percentage of participants with stable disease for ≥24 weeks or a complete response (CR) or partial response (PR).
Mean Role Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years) Mean Change from Baseline in the Role Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years) Mean Physical Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years) Mean Change from Baseline in the Physical Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years) Mean Global Health Status/Quality of Life Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years) Mean Change from Baseline in the Global Health Status/Quality of Life Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years) Number of Participants with at Least One Adverse Event, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0) From Baseline until 28 days after the final dose of study treatment (up to 8 years, 5 months) Number of Participants with Abnormalities in Clinical Laboratory Test Results From Baseline until 28 days after the final dose of study treatment (up to 8 years, 5 months)
Trial Locations
- Locations (237)
Sohag Oncology Center
🇪🇬Cairo, Egypt
Clinique Ste-Elisabeth
🇧🇪Namur, Belgium
Hospital Sao Rafael - HSR
🇧🇷Salvador, Bahia, Brazil
Pronutrir - suporte nutricional e quimioterapia ltda.
🇧🇷Fortaleza, Ceará, Brazil
Hospital Araujo Jorge
🇧🇷Goiania, Goiás, Brazil
Hospital do Câncer de Londrina
🇧🇷Londrina, Paraná, Brazil
Hospital do Cancer de Pernambuco - HCP
🇧🇷Recife, Pernambuco, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
🇧🇷Ijui, Rio Grande Do Sul, Brazil
Hospital Nossa Senhora da Conceicao
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital de Amor Amazônia
🇧🇷Porto Velho, Rondônia, Brazil
Fundação Pio XII Hospital de Câncer de Barretos
🇧🇷Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
🇧🇷Sao Paulo, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
🇧🇷Sao Paulo, São Paulo, Brazil
Affiliated Hospital of Hebei University
🇨🇳Baoding, China
Peking University People's Hospital
🇨🇳Beijing, China
the First Affiliated Hospital of Bengbu Medical College
🇨🇳Bengbu City, China
The First Hospital of Jilin University
🇨🇳Changchun City, China
Jiangsu Cancer Hospital
🇨🇳Nanjing City, China
Guangxi Cancer Hospital of Guangxi Medical University
🇨🇳Nanning City, China
The First Affiliated Hospital of China Medical University
🇨🇳Shenyang City, China
Tianjin Cancer Hospital
🇨🇳Tianjin, China
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
🇨🇴Bogota, D.C., Colombia
Clinica Colsanitas S.A. sede Clinica Universitaria Colombia
🇨🇴Bogota, Colombia
Oncomedica S.A.
🇨🇴Monteria, Colombia
Oncólogos de Occidente
🇨🇴Pereira, Colombia
Dar El salam Cancer Centre
🇪🇬Cairo, Egypt
National Cancer Institute- Breast Cancer Treatment & Research Hospital - 5th settlement
🇪🇬Cairo, Egypt
Institut Sainte Catherine
🇫🇷Avignon, France
CH de la Côte Basque - Hôpital de Bayonne
🇫🇷Bayonne, France
The First Affiliated Hospital of Xian Jiao Tong University
🇨🇳Xi'an City, China
Clinica De La Costa
🇨🇴Barranquilla, Colombia
CHU Besançon - Hôpital Jean Minjoz
🇫🇷Besançon Cedex, France
Polyclinique Bordeaux Nord Aquitaine
🇫🇷Bordeaux, France
CHU de GRENOBLE
🇫🇷Grenoble, France
CHD Vendée
🇫🇷La Roche Sur Yon, France
Hopital Prive Jean Mermoz
🇫🇷Lyon, France
INSTITUT CURIE_Site Paris
🇫🇷Paris, France
Centre Catalan D' Oncologie
🇫🇷Perpignan, France
CHU Poitiers
🇫🇷Poitiers, France
Gesundheitszentrum Wetterau, Hochwaldkrankenhaus Bad Nauheim
🇩🇪Bad Nauheim, Germany
Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie
🇩🇪Bamberg, Germany
Onkologische Schwerpunktpraxis Kurfürstendamm
🇩🇪Berlin, Germany
Gynäkologisches Zentrum Bonn
🇩🇪Bonn, Germany
Onkozentrum Dres. Göhler
🇩🇪Dresden, Germany
Kliniken Essen-Mitte
🇩🇪Essen, Germany
Dres. Andreas Köhler und Roswitha Fuchs
🇩🇪Langen, Germany
MVZ für Hämatologie und Onkologie Ravensburg GmBH
🇩🇪Ravensburg, Germany
Caritas-Krankenhaus St. Josef
🇩🇪Regensburg, Germany
Klinikum Mutterhaus der Borromaeerinnen gGmbH
🇩🇪Trier, Germany
Universitätsklinik Tübingen
🇩🇪Tübingen, Germany
Budapesti Szent Margit Korhaz
🇭🇺Budapest, Hungary
Eszak-Pesti Centrumkorhaz - Honvedkorhaz
🇭🇺Budapest, Hungary
Somogy Varmegyei Kaposi Mor Oktato Korhaz
🇭🇺Kaposvár, Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
🇭🇺Szolnok, Hungary
Komarom-Eszergom Varmegyei Szent Borbala Korhaz
🇭🇺Tatabanya, Hungary
Istituto Clinico Humanitas
🇮🇹Rozzano, Lombardia, Italy
Humanitas Centro Catanese Di Oncologia
🇮🇹Misterbianco (CT), Sicilia, Italy
Ospedale Civile
🇮🇹Livorno, Toscana, Italy
International Cancer Institute (ICI)
🇰🇪Eldoret, Kenya
Notre Dame Des Secours Hospital
🇱🇧Jbeil, Lebanon
IPO do Porto
🇵🇹Porto, Portugal
Eastleigh Breast Care Centre
🇿🇦Pretoria, South Africa
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
🇪🇸Sant Andreu de La Barca, Barcelona, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
🇪🇸Santiago de Compostela, LA Coruna, Spain
Hospital Universitario de Canarias
🇪🇸La Laguna, Tenerife, Spain
Hospital Clínic i Provincial
🇪🇸Barcelona, Spain
Hospital Universitario Clínico San Cecilio
🇪🇸Granada, Spain
Hospital Juan Ramon Jimenez
🇪🇸Huelva, Spain
Centro Oncologico MD Anderson Internacional
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria
🇪🇸Malaga, Spain
Ankara City Hospital
🇹🇷Ankara, Turkey
Uludag Uni Hospital
🇹🇷Bursa, Turkey
Dicle University Faculty of Medicine
🇹🇷Diyarbakir, Turkey
Prof. Dr. Cemil Tascioglu City Hospital
🇹🇷Istanbul, Turkey
Ac?badem Altunizade Hastanesi
🇹🇷Istanbul, Turkey
Ege Uni Medical Faculty
🇹🇷Izmir, Turkey
Katip Celebi University Ataturk Training and Research Hospital
🇹🇷Izmir, Turkey
Kocaeli University Faculty of Medicine
🇹🇷Izmit, Turkey
Erciyes Uni
🇹🇷Kayseri, Turkey
Antalya Memorial Hastanesi
🇹🇷Kepez, Turkey
Mersin City Education and Research Hospital
🇹🇷Mersin, Turkey
Ondokuz Mayis Univ. Med. Fac.
🇹🇷Samsun, Turkey
Ac?badem Maslak Hastanesi Büyükdere
🇹🇷Sar?yer/?stanbul, Turkey
Medical Park Seyhan Hospital
🇹🇷Seyhan, Turkey
Hacettepe Uni Medical Faculty Hospital
🇹🇷Sihhiye/Ankara, Turkey
Namik Kemal Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, 100
🇹🇷Tekirdag, Turkey
Karadeniz Tecnical University Medical Faculty
🇹🇷Trabzon, Turkey
Uganda Cancer Institute
🇺🇬Kampala, Uganda
University Hospital North Tees
🇬🇧Cleveland, United Kingdom
Charing Cross Hospital
🇬🇧London, United Kingdom
Maidstone Hospital
🇬🇧Maidstone, United Kingdom
Nottingham University Hospitals NHS Trust - City Hospital
🇬🇧Nottingham, United Kingdom
Royal Preston Hosp
🇬🇧Preston, United Kingdom
GHdC Site Les Viviers
🇧🇪Charleroi, Belgium
Hotel Dieu de France
🇱🇧Beirut, Lebanon
Ars Medical Sp. z o. o.
🇵🇱Pi?a, Poland
Szpital Kliniczny im. H.Swiecickiego UM w Poznaniu
🇵🇱Pozna?, Poland
Carle Cancer Center
🇺🇸Urbana, Illinois, United States
Arizona Clinical Research Center, Inc
🇺🇸Tucson, Arizona, United States
Genesis Cancer Center
🇺🇸Hot Springs, Arkansas, United States
Los Angeles Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
St Mary's Hospital and Medical Center
🇺🇸Grand Junction, Colorado, United States
Cancer Specialists of North Florida
🇺🇸Jacksonville, Florida, United States
Florida Cancer Specialists - EAST - SCRI - PPDS
🇺🇸West Palm Beach, Florida, United States
Maryland Oncology Hematology - Annapolis
🇺🇸Annapolis, Maryland, United States
St. Joseph Mercy Hospital
🇺🇸Ann Arbor, Michigan, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
St. Joseph Mercy Oakland
🇺🇸Pontiac, Michigan, United States
Queens Hospital Cancer Center
🇺🇸Jamaica, New York, United States
Clinical Research Alliance
🇺🇸Westbury, New York, United States
Hightower Clinical
🇺🇸Oklahoma City, Oklahoma, United States
West Cancer Center
🇺🇸Germantown, Tennessee, United States
Texas Oncology - Austin
🇺🇸Austin, Texas, United States
CHRISTUS Spohn Cancer Center - Shoreline
🇺🇸Corpus Christi, Texas, United States
Texas Oncology - DFW
🇺🇸Dallas, Texas, United States
Texas Oncology - El Paso
🇺🇸El Paso, Texas, United States
Millennium Physicians
🇺🇸Houston, Texas, United States
CHRISTUS St. Michael Health System
🇺🇸Texarkana, Texas, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Swedish Cancer Institute - Edmonds Campus
🇺🇸Edmonds, Washington, United States
Swedish Cancer Institute - Issaquah
🇺🇸Issaquah, Washington, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Fundación CENIT para la Investigación en Neurociencias
🇦🇷Buenos Aires, Argentina
Centro Oncologico Korben
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
🇦🇷La Rioja, Argentina
Fundacion Centro Oncologico de Integracion Regional (COIR)
🇦🇷Mendoza, Argentina
Instituto de Oncología de Rosario
🇦🇷Rosario, Argentina
Hospital Provincial del Centenario
🇦🇷Rosario, Argentina
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
🇦🇷San Juan, Argentina
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
UZ Gent
🇧🇪Gent, Belgium
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Hunan Cancer Hospital
🇨🇳Changsha City, China
Sichuan Cancer Hospital
🇨🇳Chengdu City, China
West China Hospital - Sichuan University
🇨🇳Chengdu City, China
No. 900 Hospital (Fuzhou General Hospital)
🇨🇳Fuzhou City, China
Fujian Cancer Hospital
🇨🇳Fuzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou City, China
Zhejiang Provincial People?s Hospital
🇨🇳Hangzhou, China
Shandong Cancer Hospital
🇨🇳Jinan, China
The First Affiliated Hospital Of Jinzhou Medical University
🇨🇳Jinzhou City, China
Yunnan Cancer Hospital
🇨🇳Kunming, China
The Third Hospital of Nanchang
🇨🇳Nanchang City, China
Jiangxi Cancer Hospital
🇨🇳Nanchang, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
🇨🇳Nanjing City, China
The Tumor Hospital of Xinjiang Medical University
🇨🇳Urumqi, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan City, China
Universitätsklinikum Freiburg
🇩🇪Freiburg, Germany
HOPA MVZ GmbH
🇩🇪Hamburg, Germany
Nationales Centrum für Tumorerkrankungen (NCT)
🇩🇪Heidelberg, Germany
Ärztehaus am Bahnhofsplatz
🇩🇪Hildesheim, Germany
Universitätsklinikum des Saarlandes
🇩🇪Homburg/Saar, Germany
Semmelweis Egyetem;Onkológiai Profil (Belgyógyászati és Onkológiai Klinika)
🇭🇺Budapest, Hungary
Bekes Varmegyei Központi Korhaz, Pandy Kalman Tagkorhaz
🇭🇺Gyula, Hungary
Rajiv Gandhi Cancer Inst.&Research Center
🇮🇳New Delhi, Delhi, India
Fortis Hospital
🇮🇳New Delhi, Delhi, India
Manipal Hospital
🇮🇳Bangalore, Karnataka, India
Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
Sahyadri Super Specialty Hospital Hadapsar
🇮🇳Pune, Maharashtra, India
Netaji Subhas Chandra Bose Cancer Hospital
🇮🇳Kolkata, WEST Bengal, India
TATA Medical Centre
🇮🇳Kolkata, WEST Bengal, India
Azienda Ospedaliera Universitaria Federico II
🇮🇹Napoli, Campania, Italy
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE
🇮🇹Napoli, Campania, Italy
AUSL della Romagna
🇮🇹Ravenna, Emilia-Romagna, Italy
Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
Ospedale Infermi AUSL della Romagna
🇮🇹Rimini, Emilia-Romagna, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Asst Degli Spedali Civili Di Brescia
🇮🇹Brescia, Lombardia, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
IOV - Istituto Oncologico Veneto - IRCCS
🇮🇹Padova, Veneto, Italy
King Hussein Cancer Center
🇯🇴Amman, Jordan
Aga Khan University Hospital
🇰🇪Nairobi, Kenya
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Rizk Hospital
🇱🇧Beirut, Lebanon
American University of Beirut - Medical Center
🇱🇧Beirut, Lebanon
Investigacion Oncofarmaceutica
🇲🇽La Paz, BAJA California SUR, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Jalisco, Mexico
Health Pharma Professional Research
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Iem-Fucam
🇲🇽D.f., Mexico CITY (federal District), Mexico
Filios Alta Medicina
🇲🇽Monterrey, Nuevo LEON, Mexico
Hospital Universitario
🇲🇽Monterrey, Nuevo LEON, Mexico
Hospital Zambrano Hellion TecSalud
🇲🇽Monterrey, Nuevo LEON, Mexico
Cuidados oncologicos
🇲🇽Querétaro, Queretaro, Mexico
Oncologico Potosino
🇲🇽San Luis Potosí, SAN LUIS Potosi, Mexico
Centro Estatal de Cancerologia de Chihuahua
🇲🇽Chihuahua, Mexico
Sultan Qaboos Comprehensive Cancer Care & Research Center
🇴🇲Muscat, Oman
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
🇵🇱Gdansk, Poland
Szpital Morski im.PCK
🇵🇱Gdynia, Poland
Przychodnia Lekarska KOMED, Roman Karaszewski
🇵🇱Konin, Poland
Szpital Wojewódzki im. Miko?aja Kopernika
🇵🇱Koszalin, Poland
Opolskie Centrum Onkologii
🇵🇱Opole, Poland
MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie
🇵🇱Rzeszow, Poland
Centrum Onkologii ? Instytut im. Marii Sk?odowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
🇵🇱Warszawa, Poland
IPO de Coimbra
🇵🇹Coimbra, Portugal
Hospital de S. Francisco Xavier
🇵🇹Lisboa, Portugal
Hospital da Luz
🇵🇹Lisboa, Portugal
Hospital Beatriz Angelo
🇵🇹Loures, Portugal
Hamad Medical Corporation
🇶🇦Doha, Qatar
King Faisal Specialist Hospital & Research Centre
🇸🇦Riyadh, Saudi Arabia
National Guard King Abdulaziz Medical City
🇸🇦Riyadh, Saudi Arabia
King Fahad Medical City
🇸🇦Riyadh, Saudi Arabia
Wits Donald Gordon Clinical Trial Centre
🇿🇦Parktown, Johannesburg, South Africa
University of Pretoria Oncology Department
🇿🇦Pretoria, South Africa
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei 100, Taiwan
Taipei Veterans General Hospital Office of General Surgery
🇨🇳Taipei, Taiwan
Rajavithi Hospital
🇹🇭Bangkok, Thailand
Ramathibodi Hospital
🇹🇭Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital
🇹🇭Chiang Mai, Thailand
Songklanagarind Hospital
🇹🇭Songkhla, Thailand
Adana Baskent University Hospital
🇹🇷Adana, Turkey
Ankara Oncology Hospital
🇹🇷Ankara, Turkey
Gazi Uni Medical Faculty Hospital
🇹🇷Ankara, Turkey
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
🇹🇷Edirne, Turkey
Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department
🇹🇷Erzurum, Turkey
Medipol University Medical Faculty
🇹🇷Istanbul, Turkey
Burjeel Medical City-Abu Dhabi
🇦🇪Abu Dhabi, United Arab Emirates
Tawam Hospital
🇦🇪Al Ain, United Arab Emirates
Ysbyty Gwynedd Hospital
🇬🇧Bangor, United Kingdom
Royal United Hospital
🇬🇧Bath, United Kingdom
Blackpool Victoria Hospital
🇬🇧Blackpool, United Kingdom
North Wales Cancer Treatment Centre, Glan Clwyd Hospital
🇬🇧Rhyl, United Kingdom
Queen's Hospital
🇬🇧Romford, United Kingdom
Singleton Hospital
🇬🇧Swansea, United Kingdom
Royal Cornwall Hospital
🇬🇧Truro, United Kingdom